ACTA1 and scleroderma: Targeting ALK5, using small molecule inhibitors, reverses some aspects of lesional dermal scleroderma fibroblasts but, critically, does not reduce α-SMA or CCN2 protein expression or α-SMA stress fibre formation in this cell type [2,5,6].